Memantine add-on in moderate to severe obsessive-compulsive disorder: Randomized double-blind placebo-controlled study

Journal of Psychiatric Research

Volumn 47, Issue 2, 2013, Pages 175-180

  Ghaleiha, Ali ^a   Entezari, Neda ^b   Modabbernia, Amirhossein ^b   Najand, Babak ^b   Askari, Neda ^b   Tabrizi, Mina ^c   Ashrafi, Mandana ^b   Hajiaghaee, Reza ^d   Akhondzadeh, Shahin ^b  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Institute of Medicinal Plants Iran   (Iran)

Author keywords

Adjunctive therapy; Memantine; Obsessive compulsive disorder; Randomized controlled trial

Indexed keywords

FLUVOXAMINE; MEMANTINE; PLACEBO;

ADD ON THERAPY; ADULT; APPETITE; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; NAUSEA; NERVOUSNESS; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; REMISSION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

EID: 84871490960     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.09.015     Document Type: Article

References (43)

1. Aboujaoude E., Barry J.J., Gamel N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Journal of Clinical Psychopharmacology 2009, 29:51-55.
2. Albelda N., Joel D. Current animal models of obsessive compulsive disorder: an update. Neuroscience 2012, 211:83-106.
3. Arnold P.D., Macmaster F.P., Hanna G.L., Richter M.A., Sicard T., Burroughs E., et al. Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder. Brain Imaging and Behavior 2009, 3:64-76.
4. Arnold P.D., Macmaster F.P., Richter M.A., Hanna G.L., Sicard T., Burroughs E., et al. Glutamate receptor gene (GRIN2B) associated with reduced anterior cingulate glutamatergic concentration in pediatric obsessive-compulsive disorder. Psychiatry Research 2009, 172:136-139.
5. Bhattacharyya S., Khanna S., Chakrabarty K., Mahadevan A., Christopher R., Shankar S.K. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 2009, 34:2489-2496.
6. Bloch M.H., Landeros-Weisenberger A., Kelmendi B., Coric V., Bracken M.B., Leckman J.F. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11:622-632.
7. Bronstein Y.L., Cummings J. Neurochemistry of frontal-subcortical circuits. Frontal-subcortical circuits in psychiatry and neurological disorders 2001, Guilford Press, New York.
8. Chakrabarty K., Bhattacharyya S., Christopher R., Khanna S. Glutamatergic dysfunction in OCD. Neuropsychopharmacology 2005, 30:1735-1740.
9. Coric V., Taskiran S., Pittenger C., Wasylink S., Mathalon D.H., Valentine G., et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biological Psychiatry 2005, 58:424-428.
10. Denys D., Zohar J., Westenberg H.G. The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence. Journal of Clinical Psychiatry 2004, 14(65 Suppl.):11-17.
11. Feusner J.D., Kerwin L., Saxena S., Bystritsky A. Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacology Bulletin 2009, 42:81-93.
12. Foa E.B., Liebowitz M.R., Kozak M.J., Davies S., Campeas R., Franklin M.E., et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. American Journal of Psychiatry 2005, 162:151-161.
13. Goodman W.K., Kozak M.J., Liebowitz M., White K.L. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. International Clinical Psychopharmacology 1996, 11:21-29.
14. Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Heninger G.R., Charney D.S. Efficacy of fluvoxamine in obsessive-compulsive disorder. A double-blind comparison with placebo. Archives of General Psychiatry 1989, 46:36-44.
15. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Delgado P., Heninger G.R., et al. The Yale-Brown Obsessive Compulsive Scale. II. Validity. Archives of General Psychiatry 1989, 46:1012-1016.
16. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 1989, 46:1006-1011.
17. Grant P., Lougee L., Hirschtritt M., Swedo S.E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology 2007, 17:761-767.
18. Hanna G.L., Veenstra-VanderWeele J., Cox N.J., Boehnke M., Himle J.A., Curtis G.C., et al. Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. American Journal of Medical Genetics 2002, 114:541-552.
19. Hezel D.M., Beattie K., Stewart S.E. Memantine as an augmenting agent for severe pediatric OCD. American Journal of Psychiatry 2009, 166:237.
20. Joel D. Current animal models of obsessive compulsive disorder: a critical review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:374-388.
21. Joel D., Ben-Amir E., Doljansky J., Flaisher S. 'Compulsive' lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam. Behavioural Pharmacology 2004, 15:241-252.
22. Kushner M.G., Kim S.W., Donahue C., Thuras P., Adson D., Kotlyar M., et al. d-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 2007, 62:835-838.
23. Lafleur D.L., Pittenger C., Kelmendi B., Gardner T., Wasylink S., Malison R.T., et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006, 184:254-256.
24. McGrath M.J., Campbell K.M., Parks C.R., Burton F.H. Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Research 2000, 877:23-30.
25. Pallanti S., Quercioli L. Treatment-refractory obsessive-compulsive disorder: methodological issues, operational definitions and therapeutic lines. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:400-412.
26. Pasquini M., Biondi M. Memantine augmentation for refractory obsessive-compulsive disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2006, 30:1173-1175.
27. Pigott T.A., Seay S.M. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry 1999, 60:101-106.
28. Pittenger C., Krystal J.H., Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx 2006, 3:69-81.
29. Poyurovsky M., Weizman R., Weizman A., Koran L. Memantine for treatment-resistant OCD. American Journal of Psychiatry 2005, 162:2191-2192.
30. Ramasubbu R., Ravindran A., Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000, 33:236-238.
31. Rosenberg D.R., Keshavan M.S. A.E. Bennett Research Award. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biological Psychiatry 1998, 43:623-640.
32. Rosenberg D.R., MacMaster F.P., Keshavan M.S., Fitzgerald K.D., Stewart C.M., Moore G.J. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. Journal of the American Academy of Child & Adolescent Psychiatry 2000, 39:1096-1103.
33. Rosenberg D.R., MacMillan S.N., Moore G.J. Brain anatomy and chemistry may predict treatment response in paediatric obsessive-compulsive disorder. International Journal of Neuropsychopharmacology 2001, 4:179-190.
34. Rosenberg D.R., Mirza Y., Russell A., Tang J., Smith J.M., Banerjee S.P., et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. Journal of the American Academy of Child & Adolescent Psychiatry 2004, 43:1146-1153.
35. Saxena S., Bota R.G., Brody A.L. Brain-behavior relationships in obsessive-compulsive disorder. Seminars in Clinical Neuropsychiatry 2001, 6:82-101.
36. Shmelkov S.V., Hormigo A., Jing D., Proenca C.C., Bath K.G., Milde T., et al. Slitrk5 deficiency impairs corticostriatal circuitry and leads to obsessive-compulsive-like behaviors in mice. Natural Medicines 2010, 16:598-602. 591 pp. following 602.
37. Stewart S.E., Jenike E.A., Hezel D.M., Stack D.E., Dodman N.H., Shuster L., et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. Journal of Clinical Psychopharmacology 2010, 30:34-39.
38. Storch E.A., Murphy T.K., Goodman W.K., Geffken G.R., Lewin A.B., Henin A., et al. A preliminary study of d-cycloserine augmentation of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder. Biological Psychiatry 2010, 68:1073-1076.
39. Ting J.T., Feng G. Glutamatergic synaptic dysfunction and obsessive-compulsive disorder. Current Chemical Genomics 2008, 2:62-75.
40. Welch J.M., Lu J., Rodriguiz R.M., Trotta N.C., Peca J., Ding J.D., et al. Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. Nature 2007, 448:894-900.
41. Wilhelm S., Buhlmann U., Tolin D.F., Meunier S.A., Pearlson G.D., Reese H.E., et al. Augmentation of behavior therapy with d-cycloserine for obsessive-compulsive disorder. American Journal of Psychiatry 2008, 165:335-341. quiz 409.
42. Willour V.L., Yao Shugart Y., Samuels J., Grados M., Cullen B., Bienvenu O.J., et al. Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. American Journal of Human Genetics 2004, 75:508-513.
43. Wu K., Hanna G.L., Rosenberg D.R., Arnold P.D. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacology Biochemistry and Behavior 2012, 100:726-735.